Related Experiment Video
Updated: Sep 6, 2025

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
Published on: March 4, 2014
Retromer dysfunction in amyotrophic lateral sclerosis
Eduardo J Pérez-Torres1,2, Irina Utkina-Sosunova2,3, Vartika Mishra1,2
1Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032.
Abstract:
Retromer is a heteropentameric complex that plays a specialized role in endosomal protein sorting and trafficking. Here, we report a reduction in the retromer proteins-vacuolar protein sorting 35 (VPS35), VPS26A, and VPS29-in patients with amyotrophic lateral sclerosis (ALS) and in the ALS model provided by transgenic (Tg) mice expressing the mutant superoxide dismutase-1 G93A. These changes are accompanied by a reduction of levels of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor subunit GluA1, a proxy of retromer function, in spinal cords from Tg SOD1G93A mice. Correction of the retromer deficit by a viral vector expressing VPS35 exacerbates the paralytic phenotype in Tg SOD1G93A mice. Conversely, lowering Vps35 levels in Tg SOD1G93A mice ameliorates the disease phenotype. In light of these findings, we propose that mild alterations in retromer inversely modulate neurodegeneration propensity in ALS.
Insights
Reduced retromer proteins (VPS35, VPS26A, VPS29) are found in amyotrophic lateral sclerosis (ALS). Modulating VPS35 levels impacts disease progression in ALS mouse models, suggesting retromer
Area of Science:
- Molecular Biology
- Neuroscience
- Cell Biology
Background:
- Retromer is a crucial protein complex involved in endosomal sorting and trafficking.
- Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease affecting motor neurons.
- Dysregulation of protein trafficking pathways is implicated in neurodegenerative disorders.
Purpose of the Study:
- To investigate the role of retromer components in amyotrophic lateral sclerosis (ALS).
- To determine the impact of retromer alterations on disease progression in an ALS mouse model.
- To explore therapeutic strategies targeting retromer function in ALS.
Main Methods:
- Quantification of retromer proteins (VPS35, VPS26A, VPS29) in human ALS patients and a transgenic mouse model (Tg SOD1G93A).
- Assessment of GluA1 receptor subunit levels as a functional marker of retromer activity in mouse spinal cords.
- In vivo manipulation of VPS35 levels using viral vectors in Tg SOD1G93A mice to evaluate disease phenotype.
Main Results:
- Reduced levels of VPS35, VPS26A, and VPS29 were observed in ALS patients and Tg SOD1G93A mice.
- A decrease in GluA1 levels correlated with retromer deficits in the spinal cords of Tg SOD1G93A mice.
- Overexpression of VPS35 exacerbated ALS phenotype, while reducing VPS35 levels ameliorated disease progression in mice.
Conclusions:
- Mild alterations in retromer function inversely modulate neurodegeneration in ALS.
- Retromer complex integrity and function are critical in the context of ALS pathogenesis.
- Targeting retromer pathways may offer a novel therapeutic approach for ALS.
Related Concept Videos
Cross-bridge Cycle
Export of Misfolded Proteins out of the ER
Parkinson's Disease: Overview
REM Sleep Behavior Disorder
RBD is significantly associated with...
Satellite Stem Cells and Muscular Dystrophy
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...

